Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pegasus Biologics has received CE Mark certification for the EU commercial sale of its Unite Biomatrix collagen wound dressing for treatment of diabetic foot ulcers.
Subscribe to our email newsletter
The company said that Unite Biomatrix is a novel collagen wound dressing with uncompromised strength to support the natural healing environment.
Michael Will, CEO of Pegasus, said: “Receiving CE Mark approval for Unite is a major milestone for Pegasus Biologics. It opens the door for a tremendous opportunity for our company. European surgeons have been looking for new options for the treatment of diabetic foot ulcers and have greatly anticipated the release of the Unite Biomatrix outside of the US. According to the World Health Organization, the incidence of diabetes is expected to more than double by 2030. With this, the prevalence of diabetic ulcers and other disease related complications continues to rise. We are pleased that we can now offer diabetic patients outside the US this new treatment.”